State-licensed medical marijuana reclassified as a less-dangerous drug
Trump Administration Reclassifies Medical Marijuana, Marking a Major Policy Shift
In a significant move that has long been anticipated by cannabis advocates, President Donald Trump’s acting attorney general, Todd Blanche, signed an order on Thursday reclassifying state-licensed medical marijuana as a less dangerous drug. This action moves medical cannabis from the highly restricted Schedule I classification to the more lenient Schedule III, reflecting a major policy shift at the federal level. However, this reclassification does not legalize marijuana for medical or recreational use under federal law but instead alters its regulatory framework. It grants licensed operators notable tax breaks and eases barriers to scientific research on cannabis.
Accelerating the Reclassification Process
The Trump administration’s decision to expedite the reclassification process underscores the president’s directive to his administration last December to move swiftly on the issue. While expressing his frustration with the pace during an unrelated executive order signing on psychedelics, Trump has consistently pushed for broader access to medical marijuana. Blanche emphasized that the Department of Justice is fulfilling Trump’s promise to broaden medical treatment options for Americans. “This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information,” Blanche stated.
Implications of the Reclassification Order
The reclassification order solidifies the legitimacy of medical marijuana programs in the 40 states that have adopted them, creating an expedited registration system with the U.S. Drug Enforcement Administration for state-licensed producers and distributors. Furthermore, it clarifies that researchers using state-licensed marijuana will not face penalties, and for the first time, allows medical marijuana companies to deduct business expenses on federal taxes. This policy shift represents a significant change for a government that has historically prohibited cannabis since the Marihuana Tax Act of 1937.
Critics and Supporters Weigh In
While the move has been heralded as a groundbreaking step by many advocates, it has also faced criticism. Kevin Sabet, CEO of Smart Approaches to Marijuana, criticized the decision as a tax break for “Big Weed,” suggesting it sends a confusing message about marijuana’s dangers. “Policy is now being dictated by marijuana CEOs, psychedelics investors, and podcasters in active addiction,” Sabet commented. Despite the reclassification, marijuana products not distributed through a state program remain in Schedule I, reserved for substances with high abuse potential.
Ongoing Debate and Future Prospects
The reclassification sidesteps the review process initiated under President Joe Biden and builds on nearly 43,000 public comments. While many Republican senators oppose loosening restrictions, Trump maintains his focus on combating other drugs, particularly fentanyl. The order raises questions about how states with both medical and recreational marijuana sales will navigate the new classification, particularly in places like Washington state, where many licensed stores sell tax-free products to medical patients.
As the Trump administration pushes for broader reclassification, this policy shift reflects a complex and evolving landscape in U.S. marijuana regulation. Advocates see it as a pivotal moment, while critics caution against potential repercussions and the influence of the cannabis industry on federal policy. The coming months will determine how this reclassification impacts the broader discussion on marijuana legalization and regulation in the United States.
Source: https://www.ocregister.com/2026/04/23/state-licensed-medical-marijuana-reclassified/